Research shows that a protein called ITIH5, produced by fat tissue, drives obesity and metabolic problems through a cellular pathway called PI3K/AKT. According to Gram Research analysis, when scientists reduced ITIH5 in obese mice, the animals lost weight, improved blood sugar control, and burned more calories. This discovery identifies ITIH5 as a potential new drug target for treating obesity, though human clinical trials are needed before any new therapies become available.
Researchers discovered that a protein called ITIH5, made by fat tissue in the body, plays a major role in obesity and diabetes risk. When they reduced ITIH5 in obese mice, the animals lost weight, improved their blood sugar control, and burned more calories. According to Gram Research analysis, this finding could lead to new treatments for obesity by targeting this specific protein. The study shows that ITIH5 works through a cellular pathway called PI3K/AKT, which controls how fat cells grow and multiply. Understanding this mechanism opens doors for developing drugs that could help people manage their weight more effectively.
Key Statistics
A 2026 research article published in the Journal of Molecular Cell Biology found that knocking down ITIH5 in obese mice alleviated high-fat diet-induced obesity, reduced fat cell enlargement, and improved glucose tolerance compared to control mice.
According to the 2026 study, ITIH5 overexpression in mice aggravated metabolic dysfunction and increased obesity progression, while ITIH5 reduction increased energy expenditure and improved metabolic health markers.
Research reviewed by Gram shows that ITIH5 works through the PI3K/AKT signaling pathway to promote fat cell differentiation and lipid accumulation, making it a potential therapeutic target for obesity intervention.
The Quick Take
- What they studied: How a protein called ITIH5 controls fat cell growth and contributes to obesity and metabolic problems
- Who participated: Laboratory experiments using mouse fat cells and obese mice on high-fat diets; specific human participant numbers not disclosed in abstract
- Key finding: Reducing ITIH5 levels in obese mice decreased weight gain, improved blood sugar control, and increased calorie burning, while increasing ITIH5 made obesity worse
- What it means for you: This research identifies a potential new drug target for obesity treatment, though human trials are needed before any new therapies become available. People with obesity or diabetes risk should continue following established weight management strategies while researchers develop ITIH5-targeting treatments.
The Research Details
Scientists conducted laboratory experiments using fat cells grown in dishes and living mice to understand how ITIH5 affects obesity. They used two main approaches: first, they either removed ITIH5 or added extra amounts to fat cells in the lab to see what happened to cell growth and fat accumulation. Second, they performed the same experiments in living mice, some fed normal diets and others fed high-fat diets designed to cause obesity.
The researchers measured multiple outcomes including how much fat accumulated in cells, how much inflammatory chemicals the cells produced, blood sugar control, body weight changes, and energy expenditure. They also investigated the specific cellular pathway (PI3K/AKT) that ITIH5 uses to trigger fat cell growth.
This approach allowed researchers to move from basic cell biology to whole-body effects, providing evidence that ITIH5 could be a meaningful therapeutic target. The use of both laboratory cells and living animals strengthens confidence in the findings.
This research approach is important because it identifies a specific molecular mechanism linking obesity to metabolic disease. Rather than just observing that people get obese, this study explains one of the biological processes driving obesity at the cellular level. Understanding these mechanisms is essential for developing targeted drugs that could be more effective and have fewer side effects than current obesity treatments.
The study was published in the Journal of Molecular Cell Biology, a peer-reviewed scientific journal. The research combined multiple experimental methods (cell culture, genetic manipulation, and animal models), which strengthens the reliability of findings. However, the study was conducted in mice and laboratory cells, not humans, so results may not directly translate to human treatment. The specific sample sizes for animal experiments were not provided in the abstract, making it difficult to assess statistical power. Human clinical trials would be necessary to confirm whether targeting ITIH5 is safe and effective in people.
What the Results Show
When researchers reduced ITIH5 in fat cells grown in the laboratory, the cells accumulated significantly less fat and produced fewer inflammatory chemicals compared to control cells. In living mice, knocking down ITIH5 in white fat tissue led to substantial weight loss, reduced fat cell enlargement, improved glucose tolerance (meaning better blood sugar control), and increased energy expenditure (calories burned).
Conversely, when ITIH5 was increased in mice, obesity worsened and metabolic dysfunction increased. This demonstrates that ITIH5 acts as a key driver of obesity progression. The researchers found that ITIH5 works through a specific cellular signaling pathway called PI3K/AKT, which is a well-known pathway controlling cell growth and metabolism.
The findings were consistent across multiple experimental approaches—both in isolated fat cells and in whole animals—suggesting the effect is robust and reproducible. The fact that both reducing and increasing ITIH5 produced opposite effects (weight loss versus weight gain) provides strong evidence that this protein directly controls obesity development.
Beyond weight and glucose control, the study found that reducing ITIH5 decreased adipocyte hypertrophy, which means fat cells didn’t grow as large. This is important because enlarged fat cells are associated with metabolic problems and inflammation. The reduction in inflammatory cytokine secretion (chemical signals that promote inflammation) suggests that ITIH5 also contributes to obesity-related inflammation, which is linked to type 2 diabetes and other metabolic diseases. These secondary findings indicate that ITIH5 affects multiple aspects of metabolic health, not just fat storage.
This research builds on existing knowledge that obesity involves complex cellular and molecular changes. Previous studies identified various proteins involved in fat cell development, but ITIH5’s specific role in obesity was not well understood. This study provides the first detailed mechanistic explanation of how ITIH5 drives obesity through the PI3K/AKT pathway. The findings align with broader research showing that targeting specific proteins in fat tissue can improve metabolic health, similar to how other obesity-related proteins have been investigated as drug targets.
The study was conducted entirely in mice and laboratory cell cultures, not in humans, so the results may not directly apply to human obesity. The abstract does not specify sample sizes for the animal experiments, making it impossible to assess whether the studies had adequate statistical power. The research focused on white adipose tissue (one type of fat) and may not represent all fat tissue types in the body. Additionally, while the study identifies ITIH5 as important for obesity, it doesn’t explain why ITIH5 levels become elevated in obesity in the first place. Finally, no human clinical trials have been conducted, so it’s unknown whether drugs targeting ITIH5 would be safe or effective in people.
The Bottom Line
This research suggests that ITIH5 could be a promising target for future obesity medications (moderate confidence level based on animal studies). Current evidence-based recommendations for weight management—including balanced nutrition, regular physical activity, and behavioral changes—remain the most proven approaches. People with obesity or type 2 diabetes should continue working with healthcare providers on established strategies while researchers develop and test ITIH5-targeting therapies in human trials.
This research is most relevant to people with obesity, prediabetes, or type 2 diabetes who might benefit from new treatment options. Researchers and pharmaceutical companies developing obesity medications should pay attention to ITIH5 as a potential drug target. Healthcare providers treating metabolic diseases may find this mechanism helpful for understanding disease biology. People without weight or metabolic issues don’t need to change their current health practices based on this research.
If ITIH5-targeting drugs are developed, human clinical trials would likely take 5-10 years before any new medication becomes available to the public. Even then, such drugs would probably work best as part of comprehensive weight management programs including diet and exercise. People should not expect immediate treatments based on this basic research discovery.
Frequently Asked Questions
What is ITIH5 and why does it matter for obesity?
ITIH5 is a protein made by fat tissue that controls how fat cells grow and multiply. A 2026 study found that reducing ITIH5 in obese mice decreased weight gain and improved blood sugar control, suggesting it could be a target for new obesity treatments.
Can I reduce ITIH5 levels through diet or exercise?
Current research doesn’t show that diet or exercise directly reduces ITIH5. This study suggests future medications might target ITIH5, but for now, traditional weight loss methods—balanced eating and regular activity—remain the proven approaches.
When will drugs targeting ITIH5 be available?
This is basic research in mice, not human trials. If pharmaceutical companies develop ITIH5-targeting drugs, human testing would likely take 5-10 years before any medication becomes available to the public.
Does this research apply to people or just mice?
This study was conducted in mice and laboratory cells, not humans. While the findings are promising, researchers must conduct human clinical trials to confirm whether targeting ITIH5 is safe and effective in people with obesity.
How does ITIH5 cause obesity at the cellular level?
ITIH5 activates a cellular pathway called PI3K/AKT that triggers fat cells to grow larger and accumulate more lipids. The 2026 study showed that blocking ITIH5 stopped this process, reducing fat storage and improving metabolic health.
Want to Apply This Research?
- Track weekly weight, waist circumference, and fasting blood glucose levels to monitor metabolic health improvements. Users can set targets for gradual weight loss (1-2 pounds per week) and monitor how dietary and exercise changes affect these metrics over time.
- Users can log daily food intake and exercise to identify patterns affecting weight and blood sugar. The app could provide reminders for consistent physical activity (150 minutes weekly) and help users track inflammatory markers through periodic blood work, connecting lifestyle changes to metabolic improvements.
- Establish a baseline of current weight, glucose levels, and energy levels. Check progress monthly rather than daily to avoid discouragement from normal fluctuations. Share results with healthcare providers to adjust treatment plans as needed. Track how dietary changes (reduced processed foods, increased fiber) and exercise correlate with improvements in weight and blood sugar control.
This research describes laboratory and animal studies investigating ITIH5’s role in obesity. The findings have not been tested in humans, and no ITIH5-targeting medications are currently available. This article is for educational purposes and should not be considered medical advice. People with obesity, prediabetes, or type 2 diabetes should consult with their healthcare provider about evidence-based weight management strategies and treatment options. Do not make changes to your diet, exercise, or medications based solely on this research. Future human clinical trials are necessary to determine whether ITIH5-targeting therapies are safe and effective for treating obesity in people.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.